☆ 4.4 Review

Estrogen-Receptor-Low-Positive Breast Cancer: Pathological and Clinical Perspectives

CURRENT ONCOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Immune landscape of breast tumors with low and intermediate estrogen receptor expression

Leonie Voorwerk et al.

Summary: Immune checkpoint blockade (ICB) is approved for TNBC patients and also shows responses in a subgroup of ER-positive breast cancer. The heterogeneity of ER-positive breast cancer raises the question of whether ER-negativity should be revisited as a selection criterion for ICB treatment in clinical trials.

NPJ BREAST CANCER (2023)

Add to Collection

Article Oncology

The clinical value of progesterone receptor expression in luminal breast cancer: A study of a large cohort with long‐term follow‐up

Ayat G. Lashen et al.

CANCER (2023)

Add to Collection

Article Pathology

The Clinical and Biological Significance of Estrogen Receptor-Low Positive Breast Cancer

Shorouk Makhlouf et al.

Summary: This study investigates the clinical and biological characteristics of breast cancer with low expression of estrogen receptor (ER) and finds that a proportion of ER-negative cases exist within the category of ER-low-positive breast cancer. The study suggests that repeat testing should be performed for breast cancer with 1%-9% ER expression and a cutoff of >= 10% expression should be used to define ER positivity.

MODERN PATHOLOGY (2023)

Add to Collection

Article Oncology

Clinical Behavior, Management, and Treatment Response of Estrogen Receptor Low (1-10%) Breast Cancer

Dan Moldoveanu et al.

Summary: This study compares ER-low with ER-negative and ER-positive breast cancer, and investigates the significance of PR expression within ER-low disease. The study finds that ER-low/PR- and ER-low/PR+ have similar pathological complete response rates after neoadjuvant chemotherapy, and both are more similar to the ER- group than the ER+ group.

ANNALS OF SURGICAL ONCOLOGY (2023)

Add to Collection

Article Medical Laboratory Technology

FOXC1 and SOX10 in Estrogen Receptor–Low Positive/HER2-Negative Breast Cancer: Potential Biomarkers for the Basal-like Phenotype Prediction

Ming Li et al.

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2023)

Add to Collection

Article Oncology

Oestrogen receptor low positive breast cancer: associations with prognosis

Anette H. Skjervold et al.

Summary: In this study, we examined the associations between levels of ER expression and tumour characteristics and prognosis in three large cohorts of BC patients. The results showed that ER Low Positive tumours were mainly found in Luminal B (HER2+) subtype and grade 3 tumours. The risk of death from BC was lower in ER Low Positive and ER ≥ 10% compared to ER-negative cases. Patients diagnosed in 1995 or later with ER Low Positive BCs had smaller, lower-grade tumours with lower proliferation status and similar prognosis compared to those with ER ≥ 10% tumours.

BREAST CANCER RESEARCH AND TREATMENT (2023)

Add to Collection

Article Oncology

Effect of Estrogen Receptor Expression Level and Hormonal Therapy on Prognosis of Early Breast Cancer

Kyung-Hwak Yoon et al.

Summary: This study retrospectively analyzed the clinicopathological characteristics, endocrine responsiveness, and five-year recurrence-free survival of breast cancer patients. The results showed that ERlow breast cancer has distinct features, higher recurrence rates, and no significant benefit from hormonal therapy.

CANCER RESEARCH AND TREATMENT (2022)

Add to Collection

Article Oncology

Immunotherapy for early triple negative breast cancer: research agenda for the next decade

Paolo Tarantino et al.

Summary: Advancements in the treatment of localized triple negative breast cancer (TNBC) are reshaping the landscape of this disease, with the addition of pembrolizumab showing significant improvement in survival. However, there are still questions regarding patient selection, integration with other treatments, and minimizing side effects.

NPJ BREAST CANCER (2022)

Add to Collection

Article Oncology

Clinical characteristics and survival outcome of patients with estrogen receptor low positive breast cancer

Chuanxu Luo et al.

Summary: This study compared the clinical characteristics and survival outcomes of ER-low patients with ER-high positive and ER-negative patients, finding that ER-low patients had more aggressive disease features and poorer response to endocrine therapy.

BREAST (2022)

Add to Collection

Article Oncology

De-escalation of five-year adjuvant endocrine therapy in patients with estrogen receptor-low positive (immunohistochemistry staining 1%-10%) breast cancer: Propensity-matched analysis from a prospectively maintained cohort

Yu-Wen Cai et al.

Summary: Short-term endocrine therapy for 2 to 3 years might be an alternative for patients who have ER-low positive breast cancer instead of the standard 5 years of treatment.

CANCER (2022)

Add to Collection

Review Oncology

Immune Checkpoint Blockade in Hormone Receptor-Positive Breast Cancer: Resistance Mechanisms and Future Perspectives

Ioannis A. Vathiotis et al.

Summary: Immunotherapy is less effective in hormone receptor-positive breast cancer due to immunosuppressive changes caused by estrogen receptor signaling in the tumor microenvironment. Hormone receptor-positive tumors have lower levels of programmed death-ligand 1 expression compared to triple-negative tumors and the signaling through estrogen receptor alters the immune microenvironment, rendering such tumors immunologically cold.

CLINICAL BREAST CANCER (2022)

Add to Collection

Article Oncology

Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC) (NeoPACT).

Priyanka Sharma et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Is there a role for the oncotype DX breast recurrence score genomic assay in estrogen receptor-low positive breast cancer?

Julia Giordano et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Review Endocrinology & Metabolism

Clinical implication of low estrogen receptor (ER-low) expression in breast cancer

Tomas Reinert et al.

Summary: Breast cancer is a heterogeneous disease, and the estrogen receptor (ER) remains the most important biomarker. ERlo breast tumors, with 1-10% ER expression, have similar characteristics and response to therapy as ERneg tumors, but may still have some degree of sensitivity to endocrine therapy.

FRONTIERS IN ENDOCRINOLOGY (2022)

Add to Collection

Article Oncology

Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer

Rachel Yoder et al.

Summary: This study compares the characteristics and outcomes of low estrogen receptor (ER) breast cancer with triple-negative breast cancer (TNBC). The study found no significant differences between the low-ER group and TNBC group in demographic, clinical, and treatment characteristics, as well as survival outcomes. However, the low-ER group is often excluded from clinical trials for TNBC, limiting the availability of efficacy data for novel treatments in this group.

NPJ BREAST CANCER (2022)

Add to Collection

Article Oncology

Association of H3K9me3 with breast cancer prognosis by estrogen receptor status

Meng Zhou et al.

Summary: This study revealed a close association between the prognostic value of H3K9me3 in breast cancer and ER status and expression level. High levels of H3K9me3 were associated with a better prognosis among ER-positive tumors, particularly ER-high positive tumors.

CLINICAL EPIGENETICS (2022)

Add to Collection

Article Oncology

Adjuvant endocrine therapy in patients with estrogen receptor-low positive breast cancer: A prospective cohort study

Yuxin Xie et al.

Summary: The study found that AI/T + AI combination endocrine therapy may be a reasonable treatment option for ER-low positive breast cancer patients, and treatment duration of more than 3 years is associated with better disease-free survival.

BREAST (2022)

Add to Collection

Article Oncology

Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

H. J. Burstein et al.

Summary: The 17th St Gallen International Breast Cancer Consensus Conference in 2021 was held virtually, with over 3300 participants discussing key issues related to early breast cancer diagnosis and treatment. The conference emphasized customized recommendations for breast cancer treatment, highlighting the importance of individualized clinical features in patient care.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

A. Gennari et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors

Georgia Gomatou et al.

Summary: CDK 4/6 inhibitors have shown promise in treating breast cancer, but patients often develop resistance. Studies indicate that resistance mechanisms involve aberrations of cell cycle molecules and rewiring of the cell to reduce dependence on CDK 4/6.

MOLECULAR BIOLOGY REPORTS (2021)

Add to Collection

Article Oncology

Characterization of estrogen receptor-low-positive breast cancer

Fei Fei et al.

Summary: The study analyzed clinicopathologic features and clinical outcomes of ER-low-positive breast cancers. ER-low-positive tumors showed significantly better prognosis compared to ER-negative tumors, with overlapping survival outcomes with ER-positive tumors in the entire cohort.

BREAST CANCER RESEARCH AND TREATMENT (2021)

Add to Collection

Article

Tumor mutational burden as a predictor of immunotherapy response in breast cancer

Tess A. O’Meara et al.

Oncotarget (2021)

Add to Collection

Review Oncology

Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression

Fabiana Luond et al.

Summary: Tumour heterogeneity, arising from intrinsic and extrinsic factors, has negative impacts on therapy response and prognosis. Cancer cell plasticity enables rapid adaptation to microenvironmental cues, playing a critical role in tumour progression and heterogeneity.

BRITISH JOURNAL OF CANCER (2021)

Add to Collection

Article Oncology

Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors- An analysis of 2765 patients from neoadjuvant clinical trials

Sonia L. Villegas et al.

Summary: The study found that patients with low hormone receptor expression HER2-negative breast cancer had similar treatment response and survival rates as patients with triple-negative breast cancer, while patients with strong hormone receptor-positive breast cancer had a lower pathological complete response rate but better survival rates. Low hormone receptor expression breast cancer patients were predominantly classified into a basal-like subtype based on gene expression analysis.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Tumor Dormancy: Implications for Invasion and Metastasis

Georgia Gomatou et al.

Summary: Tumor dormancy is a critical stage of cancer development where tumor cells are present but cancer does not progress. It involves both cellular and tumor mass dormancy, which are fundamental in preventing recurrence and maximizing therapeutic benefit.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Review Oncology

The prognostic and predictive impact of low estrogen receptor expression in early breast cancer: a systematic review and meta-analysis

N. -m. Paakkola et al.

Summary: Through a meta-analysis, it was found that ER-low breast cancer showed higher pathologic complete response to neoadjuvant chemotherapy compared to ER-positive tumors, but had worse disease-free survival and overall survival outcomes. ER-low expression seems to have a more similar outcome to ER-negative breast cancer. Further prospective studies are needed to determine the best treatment strategy for ER-low expressing breast cancer.

ESMO OPEN (2021)

Add to Collection

Article Cell Biology

Mechanisms of endocrine therapy resistance in breast cancer

Fahmida Rasha et al.

Summary: The most common subtype of BC is characterized by ER expression, with treatment typically involving suppression of estrogen production or hindering estrogen binding to its receptors. Despite the benefits of endocrine therapy, overcoming resistance driven by complex changes in the tumor microenvironment remains a clinical challenge, highlighting the need for further investigation into ER modulation mechanisms.

MOLECULAR AND CELLULAR ENDOCRINOLOGY (2021)

Add to Collection

Article Oncology

Outcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohort

S. Schrodi et al.

Summary: The study found that patients with HR low positive breast cancer have significantly worse survival than those with HR strongly positive tumors, but there was no significant survival difference compared to HR-negative patients. Therefore, it is suggested that current definitions and clinical relevance of HR positivity should be reconsidered, with patients with HR low positive/HER2-negative tumors potentially being treated similarly to those with triple-negative tumors.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution's experience in Korea

Yeon Hee Park et al.

Summary: The study aimed to determine the status of low ER-expressing invasive breast cancer. The results showed that patients with ER-low/HER2- breast cancer had similar outcomes as those with TNBC, indicating the need for further research on prognostic factors.

BREAST CANCER RESEARCH AND TREATMENT (2021)

Add to Collection

Review Oncology

Estrogen receptor-low breast cancer: Biology chaos and treatment paradox

Ke-Da Yu et al.

Summary: Hormone receptor testing is crucial for guiding treatment choices in breast cancer patients. The controversy lies in defining ER status and eligibility for treatment, especially regarding ER-low positive tumors. This subgroup may have unique molecular features and different therapeutic responses compared to ER-high positive tumors.

CANCER COMMUNICATIONS (2021)

Add to Collection

Article Oncology

Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy

Maria Vittoria Dieci et al.

Summary: In this study of non-metastatic triple-negative breast cancer patients, it was found that ER expression levels of 1-9% showed similar clinical behavior to ER levels of 1%, supporting the use of a 10% cut-off to define triple-negative breast cancer.

NPJ BREAST CANCER (2021)

Add to Collection

Review Oncology

Endocrine-Resistant Breast Cancer: Mechanisms and Treatment

Andreas D. Hartkopf et al.

BREAST CARE (2020)

Add to Collection

Article Oncology

The significance of highlighting the oestrogen receptor low category in breast cancer

Ivan K. Poon et al.

BRITISH JOURNAL OF CANCER (2020)

Add to Collection

Article Oncology

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

F. Cardoso et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection

Article Pathology

Receptor conversion in metastatic breast cancer: analysis of 390 cases from a single institution

Rong Chen et al.

MODERN PATHOLOGY (2020)

Add to Collection

Review Cell Biology

Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications

Emma Zattarin et al.

CELLS (2020)

Add to Collection

Article Oncology

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

F. Cardoso et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Pathology

Low Estrogen Receptor ( ER)-Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy Is Response Similar to Typical ER-Positive or ER-Negative Disease?

Alessandra Landmann et al.

AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2018)

Add to Collection

Review Oncology

Borderline ER-Positive Primary Breast Cancer Gains No Significant Survival Benefit From Endocrine Therapy: A Systematic Review and Meta-Analysis

Tong Chen et al.

CLINICAL BREAST CANCER (2018)

Add to Collection

Review Cell Biology

Breast cancer intratumour heterogeneity: current status and clinical implications

Chitra Joseph et al.

HISTOPATHOLOGY (2018)

Add to Collection

Article Oncology

Intratumoral Heterogeneity in Breast Cancer: A Comparison of Primary and Metastatic Breast Cancers

Yu-Jie Shi et al.

ONCOLOGIST (2017)

Add to Collection

Article

Navigation through inter- and intratumoral heterogeneity of endocrine resistance mechanisms in breast cancer: A potential role for Liquid Biopsies?

Florian Reinhardt et al.

TUMOR BIOLOGY (2017)

Add to Collection

Article Cell Biology

ZEB1 induces ER-α promoter hypermethylation and confers antiestrogen resistance in breast cancer

Jianbo Zhang et al.

CELL DEATH & DISEASE (2017)

Add to Collection

Review Medicine, General & Internal

Tumor Heterogeneity in Breast Cancer

Gulisa Turashvili et al.

FRONTIERS IN MEDICINE (2017)

Add to Collection

Article Oncology

Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer

T. Fujii et al.

ANNALS OF ONCOLOGY (2017)

Add to Collection

Article Oncology

High Incidence of Germline BRCA Mutation in Patients with ER Low-Positive/PR Low-Positive/HER-2 neu Negative Tumors

Rachel A. Sanford et al.

CANCER (2015)

Add to Collection

Article Pathology

Low ER plus Breast Cancer Is This a Distinct Group?

Nika C. Gloyeske et al.

AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2014)

Add to Collection

Article Oncology

Which threshold for ER positivity? a retrospective study based on 9639 patients

M. Yi et al.

ANNALS OF ONCOLOGY (2014)

Add to Collection

Article Oncology

Survival Outcomes in Breast Cancer Patients With Low Estrogen/Progesterone Receptor Expression

Alessandra Balduzzi et al.

CLINICAL BREAST CANCER (2014)

Add to Collection

Article Oncology

A Majority of Low (1-10%) ER Positive Breast Cancers Behave Like Hormone Receptor Negative Tumors

Jyothi S. Prabhu et al.

JOURNAL OF CANCER (2014)

Add to Collection

Review Medical Laboratory Technology

The many faces of estrogen signaling

Peter Vrtacnik et al.

BIOCHEMIA MEDICA (2014)

Add to Collection

Article Oncology

Effect of ASCO/CAP Guidelines for Determining ER Status on Molecular Subtype

Brenda Deyarmin et al.

ANNALS OF SURGICAL ONCOLOGY (2013)

Add to Collection

Article Oncology

Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry

Takayuki Iwamoto et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

Add to Collection

Review Cell Biology

Signaling by Estrogens

Boris J. Cheskis et al.

JOURNAL OF CELLULAR PHYSIOLOGY (2007)

Add to Collection

Review Physiology

Estrogen receptors:: How do they signal and what are their targets

Nina Heldring et al.

PHYSIOLOGICAL REVIEWS (2007)

Add to Collection

Review Oncology

Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy

XJ Cui et al.

JOURNAL OF CLINICAL ONCOLOGY (2005)

Add to Collection

Review Endocrinology & Metabolism

Mechanisms of estrogen receptor signaling:: Convergence of genomic and nongenomic actions on target genes

L Björnström et al.

MOLECULAR ENDOCRINOLOGY (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.